Last updated: 4 February 2020 at 10:54am EST

John Aunins Net Worth




The estimated Net Worth of John G. Aunins is at least $3 Million dollars as of 26 January 2020. John Aunins owns over 12,500 units of Seres Therapeutics Inc stock worth over $110,513 and over the last 9 years he sold MCRB stock worth over $2,889,913. In addition, he makes $0 as Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer at Seres Therapeutics Inc.

John Aunins MCRB stock SEC Form 4 insiders trading

John has made over 15 trades of the Seres Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 12,500 units of MCRB stock worth $13,125 on 26 January 2020.

The largest trade he's ever made was exercising 187,500 units of Seres Therapeutics Inc stock on 22 July 2016 worth over $90,000. On average, John trades about 15,944 units every 56 days since 2015. As of 26 January 2020 he still owns at least 105,250 units of Seres Therapeutics Inc stock.

You can see the complete history of John Aunins stock trades at the bottom of the page.





John Aunins biography

Dr. John G. Aunins Ph.D. serves as Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer of the Company. Prior to joining our Company, Dr. Aunins served on our Scientific Advisory Board from February 2012 to December 2012. From April 1989 to November 2011, Dr. Aunins served in various roles at Merck, most recently as Executive Science Director. At Merck, Dr. Aunins led process and product development teams for six licensed vaccines and multiple vaccine candidates. He is a Fellow of the American Institute for Medical and Biological Engineering and an adjunct Full Professor at the Instituto de Tecnologia Quimica e Biologica in Oeiras, Portugal. Dr. Aunins received his B.S. from the University of Kansas and his Ph.D. in Chemical Engineering from MIT.



How old is John Aunins?

John Aunins is 59, he's been the Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer of Seres Therapeutics Inc since 2012. There are 10 older and 9 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.

What's John Aunins's mailing address?

John's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Seres Therapeutics Inc

Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par..., and Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.



What does Seres Therapeutics Inc do?

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.



What does Seres Therapeutics Inc's logo look like?

Seres Therapeutics Inc logo

Complete history of John Aunins stock trades at Seres Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
26 Jan 2020 John G. Aunins
Chief Technology Officer and EVP
Option 12,500 $3.13 $39,125
26 Jan 2020
105,250
17 Dec 2018 John G. Aunins
Chief Technology Officer and EVP
Sale 14,282 $6.39 $91,262
17 Dec 2018
75,250
15 Nov 2018 John G. Aunins
Chief Technology Officer and EVP
Sale 14,279 $8.26 $117,945
15 Nov 2018
89,532
15 Oct 2018 John G. Aunins
Chief Technology Officer and EVP
Sale 14,279 $5.94 $84,817
15 Oct 2018
103,811
16 Jul 2018 John G. Aunins
Chief Technology Officer and EVP
Sale 14,279 $8.10 $115,660
16 Jul 2018
160,927
15 Jun 2018 John G. Aunins
Chief Technology Officer and EVP
Sale 14,279 $8.57 $122,371
15 Jun 2018
170,206
15 May 2018 John G. Aunins
Chief Technology Officer and EVP
Sale 42,837 $7.64 $327,275
15 May 2018
118,090
25 Apr 2018 John G. Aunins
Chief Technology Officer and EVP
Sale 14,279 $7.58 $108,235
25 Apr 2018
184,485
29 Aug 2016 John G. Aunins
Chief Technology Officer and EVP
Sale 9,390 $10.87 $102,069
29 Aug 2016
192,125
27 Jul 2016 John G. Aunins
Chief Technology Officer and EVP
Sale 9,250 $35.00 $323,750
27 Jul 2016
201,515
22 Jul 2016 John G. Aunins
Chief Technology Officer and EVP
Option 187,500 $0.48 $90,000
22 Jul 2016
220,155
27 Jun 2016 John G. Aunins
Chief Technology Officer and EVP
Sale 9,390 $27.23 $255,690
27 Jun 2016
32,655
31 May 2016 John G. Aunins
Chief Technology Officer and EVP
Sale 14,015 $30.05 $421,151
31 May 2016
42,045
25 Apr 2016 John G. Aunins
Chief Technology Officer and EVP
Sale 18,640 $31.94 $595,362
25 Apr 2016
56,060
28 Mar 2016 John G. Aunins
Chief Technology Officer and EVP
Sale 9,390 $23.89 $224,327
28 Mar 2016
74,700


Seres Therapeutics Inc executives and stock owners

Seres Therapeutics Inc executives and other stock owners filed with the SEC include: